These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30850677)

  • 1. Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor.
    Adamski P; Buszko K; Sikora J; Niezgoda P; Fabiszak T; Ostrowska M; Barańska M; Karczmarska-Wódzka A; Navarese EP; Kubica J
    Sci Rep; 2019 Mar; 9(1):3924. PubMed ID: 30850677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
    J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Parodi G; Bellandi B; Xanthopoulou I; Capranzano P; Capodanno D; Valenti R; Stavrou K; Migliorini A; Antoniucci D; Tamburino C; Alexopoulos D
    Circ Cardiovasc Interv; 2015 Jan; 8(1):. PubMed ID: 25552565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Koul S; Smith JG; Götberg M; Omerovic E; Alfredsson J; Venetsanos D; Persson J; Jensen J; Lagerqvist B; Redfors B; James S; Erlinge D
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e005528. PubMed ID: 29870381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel.
    van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N
    Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
    Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.
    Lapostolle F; Van't Hof AW; Hamm CW; Stibbe O; Ecollan P; Collet JP; Silvain J; Lassen JF; Heutz WMJM; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Goodman SG; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Ten Berg J; Zeymer U; Licour M; Tsatsaris A; Montalescot G;
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):173-183. PubMed ID: 30353444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study.
    De Rosa R; Palmerini T; De Servi S; Belmonte M; Crimi G; Cornara S; Calabrò P; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Genereux P; Angiolillo D; Piscione F; Galasso G
    Int J Cardiol; 2018 May; 259():20-25. PubMed ID: 29579602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial.
    Fabris E; Van't Hof A; Hamm CW; Lapostolle F; Lassen JF; Goodman SG; Ten Berg JM; Bolognese L; Cequier A; Chettibi M; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Cantor WJ; Kerneis M; Diallo A; Vicaut E; Montalescot G;
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):E369-E377. PubMed ID: 30302940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis.
    Montalescot G; van 't Hof AW; Bolognese L; Cantor WJ; Cequier A; Chettibi M; Collet JP; Goodman SG; Hammett CJ; Huber K; Janzon M; Lapostolle F; Lassen JF; Licour M; Merkely B; Salhi N; Silvain J; Storey RF; Ten Berg JM; Tsatsaris A; Zeymer U; Vicaut E; Hamm CW;
    JACC Cardiovasc Interv; 2016 Apr; 9(7):646-56. PubMed ID: 26952907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
    Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
    Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results.
    Parodi G; Dossi F; Raccis M; Talanas G; Mura E; Siciliano R; Guarino S; Marini A; Franca P; Saba PS; Sanna GD; Canonico ME
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):692-700. PubMed ID: 37591636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
    Rinaldi MJ; Gohs FX; Kirtane AJ; Brodie BR; Stuckey TD; Redfors B; McAndrew T; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Maehara A; Généreux P; Mehran R; Stone GW
    Am J Cardiol; 2019 Feb; 123(4):549-557. PubMed ID: 30527773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial.
    Liu HL; Wei YJ; Ding P; Zhang J; Li TC; Wang B; Wang MS; Li YT; Zhang JJ; Ren YH; Tang Q; Luo JP; Yang SL; Ma HY; Liu Y; Han W; Li Y; Jin ZG; Jin LM
    Can J Cardiol; 2017 Dec; 33(12):1675-1682. PubMed ID: 29173606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.